RO-104
Retinal Vascular Diseases (including neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion)
Key Facts
About RevOpsis Therapeutics
RevOpsis Therapeutics is an early-stage biotech developing multi-specific biologics for ophthalmic diseases, with an initial focus on retinal vascular disorders like neovascular age-related macular degeneration (nAMD). The company's proprietary RevMod Platform utilizes a modular, plug-and-play system built around a universal human light chain to efficiently create BiMod, TriMod, and TetraMod antibodies targeting multiple disease pathways simultaneously. Its lead candidate, RO-104, is a first-in-class TriMod biologic designed to provide pan-VEGF and Ang-2 inhibition for improved treatment of nAMD. The platform also has potential applications in oncology and immune-mediated diseases.
View full company profile